Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Google Inc (GOOG) vs Novartis AG (NVS) Price & Performance

Google IncTrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

Google Inc vs Novartis AG — how do they compare? Google Inc trades at $347.69 (market cap $4.24T), while Novartis AG trades at $143.11 (market cap $268.57B). The key difference: Google Inc is far larger — about 15.8× Novartis AG's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Google Inc for 137 Days and Novartis AG for 82 Days on average.

GOOGNVS
Market Cap
$4.24T$268.57B
Volume
13,937,9021,532,573
Sector
MediaHealth
52-Week High
$399.06$168.62
52-Week Low
$237.49$121.80
Typical Hold Time
137 Days82 Days
Enterprise Value
$4.13T$309.89B
Dividend Yield
0.26%3.31%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Google Inc

Alphabet (GOOG) trades at $347.37, up 0.81% with strong bullish technical signals. The company demonstrates exceptional fundamental strength with 2025 revenue of $402.84B and net income of $132.17B, maintaining robust profitability margins. Recent earnings beats and aggressive AI investments highlight growth momentum, though capital expenditure spikes have raised free cash flow concerns. Analyst consensus remains overwhelmingly positive with 87% buy ratings and a $435.24 price target.

Alphabet presents a compelling growth story with dominant market positioning and AI leadership, though investors face risks from regulatory scrutiny, intense competition, and significant capital expenditure requirements. The stock's current valuation appears reasonable relative to growth prospects, with technical indicators supporting near-term upside potential toward resistance levels around $350-352.

Novartis AG

Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.

The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GOOG
17% Buy83% Sell
Avg holding period · 137 Days
NVS
100% Buy0% Sell
Avg holding period · 82 Days

Top news

Latest headlines on both assets

About Google Inc

Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.

Read more on GOOG →

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS →